丙型肝炎病毒治疗药物与耐药基因突变  

Drug-Resistance Gene Mutations and Therapeutic Drugs of the Hepatitis C Virus

作　　者：邵榆岚 夏雪山[1] SHAO Yulan;XIA Xueshan(Faculty of Life and Technology,Kunming University of Science and Technology,Kunming 650500,China;Sericulture and Apiculture Research Institute,Yunnan Academy of Agricultural Sciences,Mengzi 661101,China)

机构地区：[1]昆明理工大学生命科学与技术学院,昆明650500 [2]云南省农业科学院蚕桑蜜蜂研究所,蒙自661101

出　　处：《病毒学报》2022年第5期1214-1224,共11页Chinese Journal of Virology

基　　金：云南省基础研究计划重点项目(项目号:2019FA005),题目:丙型肝炎抗病毒药物疗效影响因素与相关机制研究;云南省重大科技专项项目(项目号:2019ZF004),题目:云南省主要传染性疾病检测技术体系建立与产品开发。

摘　　要：丙型肝炎病毒(Hepatitis C virus,HCV)引起的慢性丙型肝炎全球广泛流行,严重影响人类健康,药物治疗是防控该疾病的唯一有效途径。在干扰素-利巴韦林联合疗法在丙型肝炎治疗方面获得较好成效的基础上,直接抗病毒药物(Direct-acting antiviral,DAA)尤其泛基因型靶向药物的使用,使病毒持续性应答率(Sustained virologic response,SVR)超过95%。靶向药物直接作用于病毒增殖的关键蛋白,大大提高病毒清除率,然而由于病毒基因变异产生耐药性成为治愈丙型肝炎的最大障碍。本综述围绕HCV流行与危害、现有丙型肝炎治疗药物、直接靶向抗病毒药物,从病毒多样性与耐药基因突变特征的角度,全面介绍丙型肝炎抗病毒治疗靶向药物与耐药发生。Chronic infection with the hepatitis C virus(HCV)seriously affects human health.Due to the high variability of the HCV,an efficacious vaccine is not available.Drug treatment is the only measure to prevent and control hepatitis.At present,by using direct acting antiviral(DAA)drugs,particularly the pan genotype DAA drugs,the sustained virologic response(SVR)is more than 95%.Using the key proteins of viral replication as drug targets,DAA drug can greatly increase the virus clearance rate.However,drug resistance caused by virus mutations has become a major obstacle to curing HCV infection.Herein,we summarize the prevalence and harmfulness of HCV infection,currently used DAA drugs and the drug-resistant mutations in respect of high diversity to provide guidance for the prevention and therapy of HCV infection.

关 键 词：HCV 靶向药物 DAA 耐药 

分 类 号：R373.21[医药卫生—病原生物学]